TABLE 3.
Secondary Endpoints
| A: Diabetic Patients (LSG: n = 26; LRYGB: n = 28) | |||||||
| P Values | |||||||
| End Point | Group | Baseline | Year 1 | Year 3 | Baseline Vs. Year 1 | Baseline Vs. Year 3 | Between Groups |
| Fasting Glucose (mmol/L) | LSG | 7.7 ± 0.75 | 5.8 ± 0.38 | 6.0 ± 0.32 | 0.115 | 0.211 | 0.141 |
| LRYGB | 6.7 ± 0.47 | 5.4 ± 0.23 | 5.6 ± 0.22 | 0.040 | 0.080 | ||
| HbA1C | LSG | 7.62 ± 0.38 | 6.12 ± 0.21 | 6.51 ± 0.31 | 0.005 | 0.035 | 0.129 |
| LRYGB | 7.25 ± 0.37 | 5.76 ± 0.15 | 5.97 ± 0.16 | <0.001 | 0.001 | ||
| B: Patients With Preexisting Dyslipidemia (LSG: n = 72; LRYGB: n = 56) | ||||||
| End Point | Group | Baseline | 3 Yrs | P Values Baseline to Year 3 | Between Groups | Rate of Decline Between Groups |
| Total Cholesterol | LSG | 5.67 ± 0.15 | 5.11 ± 0.93 | 0.001 | 0.053 | 0.033 |
| LRYGB | 5.42 ± 0.18 | 4.65 ± 0.14 | <0.001 | |||
| HDL | LSG | 1.13 ± 0.04 | 1.55 ± 0.06 | <0.001 | 0.661 | 0.423 |
| LRYGB | 1.13 ± 0.04 | 1.6 ± 0.06 | <0.001 | |||
| Chol/HDL ratio | LSG | 5.39 ± 0.26 | 3.9 ± 0.34 | <0.001 | 0.031 | 0.070 |
| LRYGB | 4.92 ± 0.19 | 3.01 ± 0.09 | <0.001 | |||
| LDL | LSG | 3.45 ± 0.14 | 3.16 ± 0.12 | 0.043 | 0.202 | 0.018 |
| LRYGB | 3.41 ± 0.17 | 2.78 ± 0.1 | <0.001 | |||
| TG | LSG | 2.22 ± 0.16 | 1.35 ± 0.11 | <0.001 | 0.327 | 0.368 |
| LRYGB | 2.07 ± 0.16 | 1.18 ± 0.10 | <0.001 | |||
| C: Quality of Life, All Patients (LSG: n = 107; LRYGB: n = 110) | |||||||
| End Point (Mean ± SD) | Group | Baseline | 1 Yr | 2 Yrs | 3 Yrs | Baseline Vs. Year 1 | Between Groups |
| GIQLI Score | LSG | 100.0 ± 20.6 | 126.3 ± 13.4 | 124.5 ± 16.9 | 117.4 ± 22.6 | 0.001 | 0.366 |
| LRYGB | 99.3 ± 17.5 | 128.5 ± 9.3 | 126.5 ± 14.8 | 121.2 ± 13.9 | 0.003 | ||
| BAROS QoL Score | LSG | 0.1 ± 1.2 | 1.9 ± 0.8 | 1.9 ± 0.9 | 1.7 ± 0.8 | <0.001 | 0.535 |
| LRYGB | 0.2 ± 1.3 | 1.9 ± 0.6 | 2.0 ± 0.8 | 1.7 ± 0.9 | <0.001 | ||
A: Improvement of glycemic control in diabetic patients. At 3 years there was no significant difference in fasting glucose or HbA1c between LSG and LRYGB. B: Dyslipidemia: significant improvements of lipid profiles in both groups. Rate of decline for LDL and total cholesterol was significantly higher in LRYGB group compared with LSG, adjusted for baseline values. Values are expressed as mean ± SD.
C: Quality of life measured by GIQLI score and BAROS QoL score. GIQLI score for healthy individuals = 121. After 1 year, quality-of-life scores were significantly higher than preoperatively and remained high. There was no difference between the 2 groups. Values are expressed as mean ± SD.